Lebrikizumab-Lbkz: uses, dosing, side effects & brands
Lebrikizumab-Lbkz is a medicine sold in the U.S. under one brand, for atopic dermatitis. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Atopic Dermatitis
- Available as
- Injectable
- Sold as
- Ebglyss
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How lebrikizumab-lbkz is dosed
From the FDA label for Ebglyss (application BLA761306). Other lebrikizumab-lbkz products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Prior to EBGLYSS treatment, complete all age-appropriate vaccinations according to current immunization guidelines. ( 2.1 ) The recommended dosage of EBGLYSS is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg (one injection) every 2 weeks until Week 16 or later, when adequate clinical response is achieved. The maintenance dose of EBGLYSS is 250 mg every 4 weeks or 250 mg every 8 weeks. ( 2.2 ) Administer by subcutaneous injection. ( 2.4 ) 2.1 Vaccination Prior to Administration of EBGLYSS Complete all age-appropriate vaccinations according to current immunization guidelines [see Warnings and Precautions ( 5.4 )] . 2.2 Recommended Dosage The recommended subcutaneous dosage of EBGLYSS is an initial dose of 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later, when adequate clinical response is achieved. The maintenance dosage of EBGLYSS is 250 mg every four weeks or 250 mg every eight weeks [see Pharmacodynamics ( 12.2 ) and Clinical Studies ( 14.1 )] . 2.3 Concomitant Topical Therapies EBGLYSS can be used with or without topical corticosteroids (TCS). Topical calcineurin inhibitors (TCI) may be used, but reserved for sensitive areas only, such as the face, neck, intertriginous and genital areas. 2.4 Important Administration Instructions EBGLYSS is for subcutaneous administration. EBGLYSS is…
Lebrikizumab-Lbkz side effects
The following adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Warnings and Precautions ( 5.1 )] Conjunctivitis and Keratitis [see Warnings and Precautions ( 5.2 )] Most common (≥1%) adverse reactions are conjunctivitis, injection site reactions, and herpes zoster. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying and controlled conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Atopic Dermatitis The safety of EBGLYSS was evaluated across 4 randomized, double-blind, placebo-controlled, multicenter trials in subjects with moderate-to-severe atopic dermatitis including 3 phase 3 trials (ADvocate 1, ADvocate 2, ADhere) and 1 phase 2 dose ranging trial (KGAF). In these 4 trials, mean age was 37 years; 50% of subjects were male; 62% were White, 13% were Black, and 20% were Asian. In terms of co-morbid conditions, in the phase 3 trials, 30% of the subjects had asthma, 50% had allergic rhinitis, 31% had food allergy, and 14% had allergic conjunctivitis at baseline. A total of 891 subjects were treated…
Who shouldn’t take lebrikizumab-lbkz
EBGLYSS is contraindicated in patients with prior serious hypersensitivity to lebrikizumab-lbkz or any excipients of EBGLYSS [see Warnings and Precautions ( 5.1 )] . Prior serious hypersensitivity to lebrikizumab-lbkz or any excipients in EBGLYSS. ( 4 )
Every lebrikizumab-lbkz product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Ebglyss.
What people report to the FDA about lebrikizumab-lbkz
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 16 reports naming lebrikizumab-lbkz. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- dermatitis atopic3 reports
- dry skin3 reports
- erythema2 reports
- injection site pain2 reports
- pruritus2 reports
- allergy to chemicals1 reports
- arthralgia1 reports
- blood pressure increased1 reports
Read these as a signal, not a rate. A report does not mean lebrikizumab-lbkz caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is lebrikizumab-lbkz?
Ebglyss (Lebrikizumab-Lbkz) is a medication used to treat Atopic Dermatitis.
Can you take lebrikizumab-lbkz with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run lebrikizumab-lbkz against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does lebrikizumab-lbkz come in?
Across the brands we track, lebrikizumab-lbkz is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic lebrikizumab-lbkz?
We do not currently list a generic-labelled lebrikizumab-lbkz product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Lebrikizumab-Lbkz: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/lebrikizumab-lbkz
- MLA
- “Lebrikizumab-Lbkz: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/lebrikizumab-lbkz.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for lebrikizumab-lbkz on DailyMed (NIH) ↗.